<code id='216E46C364'></code><style id='216E46C364'></style>
    • <acronym id='216E46C364'></acronym>
      <center id='216E46C364'><center id='216E46C364'><tfoot id='216E46C364'></tfoot></center><abbr id='216E46C364'><dir id='216E46C364'><tfoot id='216E46C364'></tfoot><noframes id='216E46C364'>

    • <optgroup id='216E46C364'><strike id='216E46C364'><sup id='216E46C364'></sup></strike><code id='216E46C364'></code></optgroup>
        1. <b id='216E46C364'><label id='216E46C364'><select id='216E46C364'><dt id='216E46C364'><span id='216E46C364'></span></dt></select></label></b><u id='216E46C364'></u>
          <i id='216E46C364'><strike id='216E46C364'><tt id='216E46C364'><pre id='216E46C364'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:comprehensive    - browse:71
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore